title: IBD: of mice and men-shedding new light on IL-13 activity in IBD.
abstract: a recent study in a mouse model of colitis has demonstrated that interleukin (Il)‑13, through inhibition of the mixed type 1 and type 17 T‑helper cell inflammatory response, has a protective effect. the decoyreceptor Il‑13rα2 inhibits this protective effect, suggesting blockade of Il‑13rα2 as a potential therapy for patients with IBD.
authors.affiliation: IBD Center, IRCCS Humanitas, Via Manzoni 56, Rozzano, Milan 20089, Italy. sdanese@hotmail.com
authors.forename: Silvio
authors.initials: S
authors.lastname: Danese
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D003092:Colitis / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology*; D004195:Disease Models, Animal; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D018793:Interleukin-13 / Q000378:metabolism*; D053663:Interleukin-13 Receptor alpha2 Subunit / Q000172:deficiency* / Q000235:genetics; D020381:Interleukin-17 / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D010894:Piroxicam / Q000009:adverse effects; D006377:T-Lymphocytes, Helper-Inducer / Q000473:pathology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018793:Interleukin-13; D053663:Interleukin-13 Receptor alpha2 Subunit; D020381:Interleukin-17; D010894:Piroxicam; D007371:Interferon-gamma